Prescient Therapeutics
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also new tools for clinicians in combating cancer. Prescient also has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
